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HLA-A, B, DR and Bf allotypes in patients with idiopathic membra-
nous nephropathy (IMN). Fifty—five adult biopsy—proven patients with
idiopathic membranous nephropathy were examined for HLA-A, B and
DR antigens, and for the Bf allotypes. The phenotype frequencies of
HLA-DR3 (52 vs. 23%) and HLA-B8 (46 vs. 24%) showed a significant
increase in the IMN patient group compared to those of controls from
the same region. The supraphenotype in which the combination of
DR3-B8 alleles in Bf SS homozygotes occurred was significantly more
common in the patient group than in the controls. A subset of six
individuals carrying antigens DR3, B8, and common BP'S alleles was
identified, and the clinical course of those patients was found to be
significantly worse compared to the rest of the patients. The present
results do not support the existing suggestion that the clinical course of
these diseases in Caucasians is determined by antigens B 18 and the rare
Bf allele (Bf°F1). It seems likely that IMN is not a single disease but a
renal lesion that can result from several combinations of genetic
predisposition and environmental stimuli.
Recent studies on the association of antigens of the major
histocompatibility complex (MCH) with idiopathic membra-
nous nephropathy (IMN) suggest that chromosome 6 in man
plays an important role in the pathogenetic mechanisms of this
disease. Kiouda et al [1] reported an association with the DR3
antigen as well as a significant increase in HLA-Bl8 in a group
of 48 patients with IMN. Further, from the same group of
patients an increase in the rare Bf allele (BFl) was also
reported [21, and in a subsequent study the haplotype DR3-
Bf5F1-B18 was shown to play a significant role in the progres-
sion of the disease [3]. In an investigation of IMN patients from
Germany, although a significant increase of DR3 antigen was
shown, neither the increase in HLA-B18 nor the occurrence of
the *Fl allele could be confirmed [4]; this study instead showed
significant increase of HLA-B8 which was attributed to linkage
disequilibrium between HLA-B8 and DR3 ( = 62.3). In recent
investigations, an association of DR3 and B8 has also been
reported from France [5] but the study of genetic predisposition
to IMN in two Japanese populations gave different results and
showed a significant increase in the DR2 antigen [6, 71. The
present investigation describes the distribution of Bf allotypes
and HLA-A, B and DR antigens in a group of IMN patients
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from northeast England, and data are examined to investigate
aspects of genetic predisposition and the prognostic value of
these antigens in this disease group.
Methods
Fifty—five Caucasian patients, from northeast England, 44
males (aged 27 to 77 years) and 11 females (aged 27 to 68 years),
in whom the histological criteria were fulfilled for diagnosis of
membranous glomerulonephritis on renal biopsy, were taken
for the study. The biopsy specimen was examined by light
microscopy, in all, with silver methanamine staining in 45 out of
55, by irnmunofluorescence in 23 out of 55, and by electron
microscopy in 29 out of 55 patients. The ten cases in whom
silver methanamine staining, immunofluorescence, or electron
microscopy had not been performed were diagnosed before
these techniques were routinely employed. The primary causes
of the disease such as syphilis, gold, pencillamine, and SLE
were excluded by detailed clinical, biochemical, and serological
investigations. The patients have been followed for one to 27
years from the onset of the disease. Serum creatinine levels
were taken as an index of renal function at the time of
investigation. Ten of the 55 patients had progressed to end—
stage renal disease and required dialysis or renal transplanta-
tion.
All patients were investigated for HLA-A, B and DR antigens
and Bf allotypes. The controls were healthy adult individuals
matched for the region of birth, most in the northeast of
England, and these included hospital and university staff mem-
bers. With commercially available antisera (Biotest, Mosley,
Birmingham, England) and some donated by the National
Institutes of Health, Bethesda (Maryland), HLA typing was
performed using standard microcytotoxicity assay with incuba-
tion at 37°C for one hour. Altogether 84 antisera were used to
identify 15 specificities of HLA-A, 22 specificities of HLA-B
and seven specificities of DR loci.
Bf allotypes were examined by a modification of the method
of Alper and Propp [8] as described previously from this
laboratory [9].
Statistical significance was examined by Fisher's exact prob-
ability test. Each P value thus obtained was corrected by a
factor of 44 for the number of antigens tested to take into
account the possibility that apparently significant association
may arise by chance when many tasks are performed simulta-
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Table 1. HLA Al, A3, B8, B18, DR antigens and Bf phenotypes in
IMN patients and control
Patients Controls
observed
position %
observed
positive %
Fisher's
exact P
Relative
risk
HLA
Al
A3
B8
B18
DR1"
DR2
DR3
DR4
DR5
DR6
DR7
neg
BFC
S
SF
F
SF'
SS'
Total
28
9
25
4
3
15
28
16
11
9
8
3
38
11
2
2
2
55
51.3
16.6
45.5
7.2
5.6
27.8
51.8
29.6
20.3
16.7
14.8
69.2
20.0
3.6
3.6
3.6
413 41.3
258 25.8
240 24.0
79 7.9
12 17.1
26 37.1
16 22.8
13 18.5
13 18.5
11 15.7
18 25.7
3
52 74.3
14 20.0
3 4.3
— 0.0
1 1.4
70
0.1030
0.0753
006d
0.5614
0.0430
0.1820
00007d
0.1098
0.4881
0.5377
0.1036
0.3280
0.5900
0.6130
0.1920)
0.4100)
1.51
0.57
2.64
0.90
0.28
0.65
3f4
1.85
1.27
1.07
0.50
0.78
1.00
0.83
a Number of samples tested for HLA A
patients = 55
b Number of samples tested for HLA-DR controls = 70, patients =
54
c Bfgene frequencies are: patient BF = 0.137; *5 = 0.827; BrF' =
0.018; BS = 0.018; and control Bf'F = 0.143; Bf*S = 0.850; Bf'F' =
0.000; Bf'S' = 0.007d P was significant after correction
neously. The relative risk was calculated as described by
Svejgaard and Ryder [10].
To examine the role of the antigens of the major histocom-
patibility region in predisposition to IMN and their prognostic
value, the patients were divided into three groups according to
their renal function at the time of the survey: 1) stable—plasma
creatinine level below 200 tmol/liter; 2) chronic renal failure—
plasma creatinine level above 200 j.tmol/liter, but not on renal
replacement therapy; and 3) end—stage renal disease—on re-
placement therapy (dialysis or transplantation).
Results
The complete analysis of the HLA-A, B, DR and Bf systems
for each patient is given in Appendix 1, together with details of
the duration of follow—up and the patient's renal status at the
time of last examination. The relative rarity of the disease
necessitates publication of such information in detail so that the
data from various centers can later be pooled and examined
simultaneously.
HLA-A and B antigens showing a noticeable difference in
frequencies between IMN patients and controls, along with the
frequencies of the seven DR antigens and the Bf allotypes, are
listed in Table 1. Twenty—eight (51.8%) IMN patients had the
DR3 antigen compared to sixteen controls (22.8%). This differ-
ence was highly significant (P = 7 x 10) and remained so
when corrected for the number of antigens tested (Pc = 3 )<
lO_2). The relative risk calculated for DR3 antigen was 3.64.
The only other significant difference in DR antigen was a
and B controls = 1000,
decrease in frequency of the DR1 antigen in IMN patients, but
after correction this significance was lost.
The HLA-Al antigen showed a 10% increase in frequency in
patients and a similar decrease was found for HLA-A3, but
these differences between patient and control groups were not
significant. HLA-B8 was detected in 25 patients (45.5%) com-
pared to 240 controls (24%). This difference in antigen B8
frequency was significant both before and after correction (P =
6 x io; Pc = 2.6 x 10—2). The B18 antigen frequencies in both
patients and control groups were almost identical.
For the Bf system there were four rare variants in the patient
group compared to one in the control population. Two patients
showed the presence of the rare mutant allele *Fl whereas the
other two showed the presence of *S 1 allele. Only the *S 1 allele
was seen in the present control group, but in a larger sample
from northeast England *F1 allele was also found in the normal
population with gene frequency of 0.2% and the *Sl allele with
similar frequency to the present patient group [11]. Overall the
distribution of Bf phenotypes did not differ significantly be-
tween the patient and control groups.
In Table 2 supraphenotypes (presence of allele irrespective of
their chromosomal location) derived by the combination of
DR-B-Bf types were compared between IMN patients and
control groups. Among the three combinations tested (DR3-B8-
Bf-SS; DR3-B8-Bf-SF and DR3-B18-Bf-SS) the frequency of
the combination of DR3-B8-BfSS was much higher in patients
compared to the control group (33.3. vs. 11.4, respectively).
The difference is highly significant (P = 0.003) and even when
corrected for the number of combinations tested the difference
still remains significant (P = 0.009). No other combination of
alleles showed any significant difference.
The correlation between renal status and the presence of
particular antigens is presented in Table 3. Nine patients (17%)
with the B8 antigen had chronic renal failure and end—stage
renal disease. Six of these nine patients (67%) had the antigen
DR3 and five of these six (83%) were homozygous for the usual
or common Bf"S allele whereas the sixth patient had the Bf*S
allele in heterozygote combination with usual or common F
allele. No patient with B 18 or a rare Bf allele had chronic renal
failure or end—stage renal disease.
Discussion
In man the role of the major histocompatibility complex in the
immunopathogenetic mechanism of IMN is still uncertain. In
Table 4, the antigen frequencies of B8, B 18 and DR3 antigen are
compared in IMN patients from different countries. There is an
elevation of DR3 frequency in IMN patients from Germany (76
vs. 23%), Spain (67 vs. 21%), France (54 vs. 20%) and from
Manchester in UK (75 vs. 20%). These investigations in Euro-
pean populations and our own are consistent in the increase of
DR3 antigen, but the study of IMN patients from two popula-
tions in Japan showed a different association. A significant
increase in DR2 antigen and relatively low values of DR3, DR4,
and DRw9 antigens were seen in these East Asian patients. The
present report which relates to one of the largest samples of
IMN patients from a single region, confirms the association of
DR3 antigen with IMN in European patients, although the
relative risk found is rather low (3.64) compared to that in
previous studies which varied from 7.5 to 12.0 [1, 4, 5].
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Table 2. Distribution of DR3, B8 or B18 and Bf supratypes in IMN patients and controls
.
Antigen present
Phenotypes
DR-B-BF
IMN patients
N = 54
Controls
N = 70
.Fisher s
exact
probability
Pa
Relative
risk
number
observed %
number
observed %
3
3
3
8 HomozygousSS
8 Heterozygous S/F
18 Homozygous SS
18
2
1
33.3
3.7
1.9
8
2
2
11.4
2.8
2.8
0.003
0.587
0.597
3.9
1.3
0.6
a Uncorrected P Value
Table 3. Correlation of renal status with patient phenotypes
Renal status
End—stage
Chronic renal renal disease
Stable (S) failure (C) (E)
number number number
Antigen present observed % observed % observed %
B8 16 30.2 4 7.5 5 9.4
B18 3 5.7 0 0.0 0 0.0
DR3 20 37.7 4 7.5 3 5.7
B8 DR3 13 24.5 3 5.7 3 5.7
B18 DR3 3 5.7 0 0.0 0 0.0
B8 DR3 BfS 13 24.5 2 3.8 3 5.7
B8 DR3 BfSF 1 1.9 1 1.9 0 0.0
B18 DR3 BfS 1 1.9 0 0.0 0 0.0
B18 DR3 BfF' 2 3.8 0 0.0 0 0.0
Other 17 32.1 5 9.4 7 13.2
Among other with DR3 3 5.7 1 1.9 0 0.0
Total 35 66.0 8 15.1 10 18.9
The samples listed in Table 4 from six countries do not agree
over the increase in B8 or B18 antigens. There is a consistent
increase in HLA-B8 frequency in patients of all these countries.
However, when compared with control data from the respec-
tive countries and corrected for the number of antigens tested
only the German study and the present investigation maintained
significance. For antigen B 18 there was an increase in the UK
(Manchester) and Spain (P < 0.024 and P < 0.05, respectively).
Both B8 and Bl8 antigens show linkage disequilibrium positive
with HLA-DR3 and respectively negative and positive with
DR2, so one possible reason for this disagreement between
series may be genetic heterogeneity and differing frequencies of
the haplotypes HLA-B8-DR3, HLA-B 1 8-DR3, HLA-B8-DR2
and HLA-B 18-DR2 in these populations.
The haplotype Al-B8-DR3 shows pronounced linkage
disequilibrium in European populations. One reason for such
highly positive linkage disequilibrium between certain alleles
may be certain epistatic mechanisms which are poorly under-
stood. It is therefore possible that the association of a disorder
with individual alleles (B8, Bl8, DR3, S or Bf'Fl) may not
represent the critical locus, and the real susceptibility may
result from the presence of various related genes. The combi-
nation of these selected alleles at different loci is here referred
to as a supraphenotype. Our supraphenotype analysis showed
that the combination DR3-B8 in Bf SS homozygotes is three
times more prevalent in IMN patients than in the control group
and the calculated relative risk for this supratype is 3.9. This
observation suggests that these three antigens (B8, DR3 and
BfS) may be one of the factors, for the genetic predisposition to
IMN.
In the present investigation of IMN patients, HLA-DR3 is in
closer linkage disequilibrium with HLA-B8 than with HLA-
B18. This probably accounts for the discrepancy between our
results and those of a neighbouring part of England [1] where
17.5% of patients had the DR3BfKFlBl8 haplotype/supratype.
In this subset of patients the clinical course was one of
deterioration [3]. Our results do not accord with this observa-
tion since among our 55 patients only two (3.7%) had this
combination of DR3Bf*FlBl8, and neither of these sustained
any deterioration of renal function during prolonged observa-
tion of their disease (nine and 17 years).
The increase in DR3 is confirmed from various European
studies but there is conflicting evidence concerning the increase
of BfFI allele in IMN. Our results at present do not support the
*Fl allele as a marker for susceptibility to IMN and are in
agreement with the French and German studies [4, 121 and
contrast with those from the neighbouring population of
Manchester [21. If the *Fl allele is a genetic marker it is a very
uncommon one among patients with IMN seen in the northeast
of England.
In conclusion it appears that in addition to the alleles of
antigens B8, B18, DR3, BS and Bf'Fl, there are additional
factors as yet unknown which determine the deterioration of
renal status in these patients, This is particularly true in the light
of recent evidence from three families with membranous
nephropathy, in which one pair of HLA identical twins and two
pairs of brothers developed IMN at different ages and followed
different clinical courses of the disease [13]. The additional
factors may include those from the environmental influences
which interact with humoral and cellular immune functions,
which are directly controlled by genes of DR antigens and genes
closely linked to the DR locus (Ir genes), or there may be class
III antigens of the MHC region which have not yet been
considered in relation to IMN. Inherited complement deficiency
(C2 component) has been shown as one of the genetic factors
predisposing to human nephritis [14]. A recent investigation
showed strong linkage disequilibrium between the null (silent)
allele of C4A and C4B loci with antigens DR3, B8 and B18 [15],
thus suggesting a possible relevance of C4 null allele in the
pathogenesis of this disease which needs to be investigated.
Renal function often declines very slowly in IMN. All the
studies listed in Table 4 and the present one have been partly or
wholly cross—sectional and based on variable period of obser-
vation. Further insight in the role of gene susceptibility in IMN
will require prospective longitudinal studies and investigation of
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Table 4. Antigen frequencies of IMN and controls in diiferent countries
Number Number
tested B8 B18 tested
Origin of sample Reference population (HLA-B) % % (HLA-DR) DR3 %
United Kingdom [11 Control
IMN
230
48
28.3
45.8
5.7
22.9
60
32
20.0
75.0
West Germany [41 Control
IMN
122
21
20.0
57.0
—
0.0
122
—
23.0
76.2
Spain [161 Control
IMN
82
39
7.0
15.0
11.0
46.0
—
—
21.0
67.0
United States [161 Control
IMN
318
33
16.0
30.0
7.0
15.0
—
—
21.0
33.0
France [51 Control
IMN
104
33
14.4
18.5
—
—
74
31
20.3
54.8
Japana [61 Control
IMN
950
50
0.2
0.0
0.0
0.0
884
50
80.0
0.0
Japanb [71 Control
IMN
140
50
0.7
2.0
—
—
158
50
1.3
0.0
United Kingdom Present
study
Control
IMN
1000
55
24.0
45.5
7.9
7.2
70
54
22.8
51.8
a DR-2 Patient vs. control (80 vs. 36%) Pc = 6.9 X 10-8
b DR-2 Patient vs. control (74 vs. 30%) Pc = 1 x l0
the MHC region in the families of patients. Such studies are
now in progress.
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Appendix 1. HLA-A, B, DR antigens, Bf-alles and renal status of
patients with idiopathic membranous nephropathy (IMN)
Duration
of
follow-
s, up Renal
No. Patient A B DR Bf (months) statusa
I CA. 1, 2 7, 8 2, 5 S 37 S
2 L.H. 1, 2 7, 8 2, 3 S 50 S
3 W.T. 1, 29 8 — 2, 3 S 96 S4 J.B. w24, 28 22, w49 neg F 132 C
5 A.Y. 2— 7, 18 3, 4 SF1 202 S
6 A.S. 1, 2 15, 17 3, 4 S 94 C
7 D.W. w24, 25 w39, 18 3 — S 51 S
8 T.G. 1, 3 7, 8 2. 3 S 28 C
9 J.M. 2— 13, w44 5, 7 SF 60 S
10 W.B. 1, w31 8, 27 3 — SF 28 C
11 GA. 1,3 8, 14 NA S 48 E
12 R.O.B. 1,2 8— 3,7 S 168 S
13 P.B. 21, 28 w22, w35 4, 5 SF 121 S
14 R.J.B. 1, 11 8— 3, 6 S 10 S
15 W.M. 2— 27,w44 1,3 SF 173 S
16 M.S. 1 — 8 — 3 — 5 55 S
17 J.D. I — 8 — 3 — S 26 S
18 K.C. 1 2 27, w44 2, 4 SF 80 519 iA. 2, 29 w44 — 4, 5 SF 151 S
20 ED. 1,2 8— 3— S 71 C
21 D.B. w24— 27— 4,5 S 55 5
22 G.H 2, 29 17, w44 4, 5 5 23 E
23 G.R. 2, 28 w35, 40 6, 7 SS' 40 E
24 S.H. I — 8 — 4 — S 44 C
25 B.H. 1, w30 8, w35 3 — 5 19 E
26 G.C. 3, 9 7, 15 2, 6 5 22 5
27 L.C. 9, w19 7,8 3— S 11 S
28 A.R. 1 — 8 — 3 — 5 21 E
29 I.C. 2 — w35, w44 4, 5 S 18 C
30 SM. 2,9 15, 27 1, 7 5 15 5
31 J.E. 2— 8, w21 3, 5 S 19 5
32 J.J. 2, w32 7, 14 2, 7 S 14 S
33 D.B. w24 — w35, w39 3, 5 5 — NA
34 A.S. 2— 7, 40 3, 6 S 6 5
35 F.K. 28 — 27, w35 5 — S — NA
36 J.H. 1, 2 8, 15 3, 4 S 75 E
37 W.O.R. 1, w19 14, 18 2, 7 S 86 5
38 M.M. 1, 2 8, 12 7, — S 163 E
39 TM. 3, — 8, 14 3, 6 SF 44 5
40 E.T. 1, 2 7, 8 2,3 S 100 5
41 D.W. 1, w19 8, 40 3, 4 S 59 S
42 ow. 1,2 w44— neg SF 142 5
43 iL. 3, w24 7, w55 neg F 32 E
44 J.R.H. 2, 29 w40 4, 6 S 99 E
45 J.A.M. 1, 3 7— 2, 4 S 101 C
46 W.K. 1, w31 7, 17 6,7 S 34 E
47 K.t. 1, 2 8, w44 3, 5 5 90 S
48 A.R. 3,219 8, 40 2, 6 S 71 S
49 SW. 2, 10 7, w35 I, 2 SF 89 5
50 R.D. 2, 3 7, 15 2, 4 SF 90 S
51 W.P. 2, 11 18, w44 3,4 SF1 109 S
52 A.R. 2,9 w21,40 3,6 SS1 312 5
53 N.F.G. 1, 11 7, w41 2, 4 SF 142 5
54 E.C. 1,11 8,w22 3— S 106 5
55 G.W. 1, 3 7, 8 2, 3 S 3 S
a NA, not available; S. stable; C, chronic renal failure; E, end—stage
renal disease
